Bing-he Xu

Bing-he Xu, P. Yuan, Jiayu Wang, 2013, Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban.

Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study

Bing-he Xu, Qing Yang, Jian-ping Xu, 2018, British Journal of Cancer.

Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial

Bing-he Xu, P. Yuan, F. Ma, 2016, Oncotarget.

A single-nucleotide polymorphism in the 3′-UTR region of the adipocyte fatty acid binding protein 4 gene is associated with prognosis of triple-negative breast cancer

D. Lin, Dianke Yu, F. Du, 2016, Oncotarget.

Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.

H. Gómez, Bing-he Xu, M. Desilvio, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators: A Phase 2 Randomized Clinical Trial.

Yang Luo, Bing-he Xu, Z. Shao, 2021, JAMA oncology.

The molecular tumor burden index as a response evaluation criterion in breast cancer

Wen-na Wang, Bing-he Xu, Y. Guan, 2021, Signal Transduction and Targeted Therapy.

Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer: a meta-analysis and systemic review of randomized clinical trials

Wenjie Zhu, Bing-he Xu, 2020, Frontiers of Medicine.

Pamiparib dose escalation in Chinese patients with non‐mucinous high‐grade ovarian cancer or advanced triple‐negative breast cancer

Yongmei Yin, Bing-he Xu, S. Mu, 2020, Cancer medicine.

Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study

Yongmei Yin, Bing-he Xu, Huiping Li, 2020, Breast Cancer Research and Treatment.

Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study

Bing-he Xu, H. Qian, F. Ma, 2019, BMC Cancer.

Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial.

Ying Cheng, Bing-he Xu, Wei Li, 2019, European journal of cancer.

Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study

Yang Luo, Bing-he Xu, P. Yuan, 2019, Oncology letters.

First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers

Y. Li, W. Qiu, B. Ye, 2019, BMC Cancer.

Development and External Validation of a Clinical Nomogram for Individually Predicting Survival of Metaplastic Breast Cancer.

Yang Luo, Bing-he Xu, F. Ma, 2022, Clinical breast cancer.

Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience.

E. Perez, J. Baselga, A. Wolff, 2013, The oncologist.

Association of GWAS-Identified Lung Cancer Susceptibility Loci with Survival Length in Patients with Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy

Hongbing Shen, W. Tan, Chen Wu, 2014, PloS one.

Tumor senescence leads to poor survival and therapeutic resistance in human breast cancer

Bing-he Xu, F. Ma, Dan Lv, 2023, Frontiers in Oncology.

Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review.

Jie He, Bing-he Xu, Zhao Yan, 2019, The Lancet. Oncology.

Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage

Fang Liang, Shaochuan Li, Bing-he Xu, 2020, Frontiers in Oncology.

[Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms].

W. Tan, X. Miao, Bing-he Xu, 2006, Zhonghua zhong liu za zhi [Chinese journal of oncology].

Abstract PD4-03: OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

M. Robson, Bing-he Xu, N. Tung, 2020 .

The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma

Bing-he Xu, Hai-juan Wang, H. Qian, 2016, Medicine.

Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC)

Bing-he Xu, Hai-juan Wang, Chen Lin, 2017, Medicine.

53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells

Weimin Zhang, Yang Luo, Bing-he Xu, 2016, BMC Cancer.

Sex-Based Heterogeneity in the Clinicopathological Characteristics and Prognosis of Breast Cancer: A Population-Based Analysis

Bing-he Xu, Yiqun Han, Jiayu Wang, 2021, Frontiers in Oncology.

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer

Yang Luo, Bing-he Xu, Y. Shao, 2021, Cancer biology & medicine.

E. Perez, Wenjie Zhu, Bing-he Xu, 2015, PloS one.

Treatment patterns for adjuvant docetaxel-based chemotherapy in early-stage breast cancer in China: A pooled retrospective analysis of four observational studies.

Bing-he Xu, Z. Shao, Zefei Jiang, 2018, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis

Wen-na Wang, Bing-he Xu, Jiayu Wang, 2018, Breast Cancer Research and Treatment.

Activity of melphalan in combination with the glutathione transferase inhibitor sulfasalazine

Bing-he Xu, M. Levitt, Shivendra V. Singh, 2004, Cancer Chemotherapy and Pharmacology.

HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials

Bing-he Xu, Ji Zhu, Lijie Zhang, 2020, Annals of translational medicine.

Advances in medical treatment of breast cancer in 2022

Bing-he Xu, V. Kaklamani, J. Zhai, 2023, Cancer innovation.

Genome-wide examination of genetic variants associated with response to platinum-based chemotherapy in patients with small-cell lung cancer

J. Ott, Chen Wu, D. Lin, 2010, Pharmacogenetics and genomics.

XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population.

W. Tan, D. Lin, Bing-he Xu, 2008, Lung cancer.

TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy

Bing-he Xu, P. Yuan, F. Ma, 2012, Breast Cancer Research and Treatment.

Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China.

F. Du, Bing-he Xu, Faxiang Ji, 2016, World journal of gastroenterology.

Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer

X. Yi, Z. Liao, Bing-he Xu, 2020, International journal of cancer.

Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

P. Neven, L. Chow, P. Goss, 2014, The oncologist.

Outcomes of re-treatment with first-line trastuzumab plus taxane in patients (pts) with metastatic breast cancer (mBC) who relapsed after (neo)adjuvant trastuzumab: A prospective multicenter study.

Bing-he Xu, Q. Sun, Shiying Yu, 2016 .

Association between Lymph Node Ratio and Disease Specific Survival in Breast Cancer Patients with One or Two Positive Lymph Nodes Stratified by Different Local Treatment Modalities

Wenjie Zhu, Bing-he Xu, R. Hong, 2015, PloS one.

Decreased Serum HDL at Initial Diagnosis Correlates with Worse Outcomes for Triple-Negative Breast Cancer but Not Non-TNBCs

Bing-he Xu, P. Yuan, F. Ma, 2015, The International journal of biological markers.

Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.

Wei Li, Shiying Yu, Quchang Ouyang, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial

Bing-he Xu, I. Bondarenko, Wei Li, 2021, BioDrugs.

Analysis of the activity and safety of weekly low‐dose bevacizumab‐based regimens in heavily pretreated patients with metastatic breast cancer

Bing-he Xu, P. Yuan, F. Ma, 2018, Thoracic cancer.

Metronomic therapy in advanced breast cancer and NSCLC: vinorelbine as a paradigm of recent progress

Bing-he Xu, T. Sun, Shusen Wang, 2020, Expert review of anticancer therapy.

Efficacy of Oral Etoposide in Pretreated Metastatic Breast Cancer: A Multicenter Phase 2 Study: Erratum

Bing-he Xu, L. Di, Qi Zhu, 2015, Medicine.

Efficacy of Oral Etoposide in Pretreated Metastatic Breast Cancer

Peng Yuan, Li Li, Min Yan, 2015, Medicine.

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.

Ying Cheng, Yongmei Yin, Bing-he Xu, 2020 .

Oral etoposide monotherapy is effective for metastatic breast cancer with heavy prior therapy.

Peng Yuan, Pin Zhang, Fei Ma, 2012, Chinese medical journal.

Abstract PS11-26: A phase 1 study of D-0502, an orally bioavailable SERD, for advanced or metastatic HR-positive and HER2-negative breast cancer

D. Juric, Bing-he Xu, Yaolin Wang, 2021 .

The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer

Yang Luo, Bing-he Xu, F. Ma, 2019, Cancer communications.

Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China

Y. Qiao, Jin-Hu Fan, Yongmei Yin, 2021, Frontiers in Oncology.

Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer

F. Du, Yang Luo, Bing-he Xu, 2016, Chinese journal of cancer.

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes

G. Hortobagyi, H. Gómez, Bing-he Xu, 2010, Breast Cancer Research and Treatment.

First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer

Bing-he Xu, I. Bondarenko, Q. Wang, 2019, Annals of Oncology.

Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors.

Yi-long Wu, Bing-he Xu, L. Trandafir, 2016, Anticancer research.

Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA

G. Lippi, Yang Luo, Bing-he Xu, 2021, Cancer biology & medicine.

Interpretation of specification for breast cancer screening, early diagnosis, and treatment management in Chinese women

Yuntao Xie, Anhua Li, Yong Wang, 2021, Journal of the National Cancer Center.

[Serum her-2/neu level and related factors in patients with breast cancer].

Bing-he Xu, P. Yuan, J. Qi, 2003, Zhonghua zhong liu za zhi [Chinese journal of oncology].

Genome-wide chromosomal instability by cell-free DNA sequencing predicts survival in patients with metastatic breast cancer

Bing-he Xu, Z. Qian, F. Ma, 2020, Breast.

ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy

X. Yi, Wenjie Zhu, Bing-he Xu, 2016, Oncotarget.

Validity of distress thermometer for screening of anxiety and depression in family caregivers of Chinese breast cancer patients receiving postoperative chemotherapy

Bing-he Xu, J. Cai, F. Ma, 2020, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR‐1210), a novel anti‐PD‐1 antibody

Bing-he Xu, B. Lan, H. Mo, 2019, Thoracic cancer.

Goserelin plus letrozole as first- or second-line hormonal treatment in premenopausal patients with advanced breast cancer.

Bing-he Xu, P. Yuan, F. Ma, 2011, Endocrine journal.

Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.

Yongmei Yin, Bing-he Xu, Huiping Li, 2017, The Lancet. Oncology.

Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

Peng Yuan, Jiayu Wang, Pin Zhang, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of Epirubicin Plus Paclitaxel vs Epirubicin and Cyclophosphamide Followed by Paclitaxel on Disease-Free Survival Among Patients With Operable ERBB2-Negative and Lymph Node–Positive Breast Cancer

Yang Luo, Bing-he Xu, P. Yuan, 2023, JAMA network open.

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients

Yang Luo, Bing-he Xu, P. Yuan, 2019, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer

Yang Luo, Bing-he Xu, Yun Wu, 2022, Breast Cancer Research and Treatment.

The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study

Bing-he Xu, Yun Wu, Yiqun Han, 2022, International Journal of Clinical Oncology.

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis

Yang Luo, Bing-he Xu, P. Yuan, 2019, Cancer management and research.

CMAR_A_198962 4699..4706

Yang Luo, Bing-he Xu, P. Yuan, 2019 .

Is it safe to give anthracyclines concurrently with trastuzumab in neo-adjuvant or metastatic settings for HER2-positive breast cancer? A meta-analysis of randomized controlled trials

Wenjie Zhu, F. Du, Bing-he Xu, 2014, Medical Oncology.

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer

F. Du, Bing-he Xu, P. Yuan, 2023, Cancer biology & medicine.

Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China

Yang Luo, Bing-he Xu, P. Yuan, 2021, Breast.

Tumor-derived microparticles promote the progression of triple-negative breast cancer via PD-L1-associated immune suppression.

Bing-he Xu, S. Qiu, Xiaonan Zheng, 2021, Cancer letters.

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple‐negative breast cancer

J. Ragaz, Bing-he Xu, Zefei Jiang, 2014, International journal of cancer.

Development and validation of a nomogram for predicting survival of advanced breast cancer patients in China

Yang Luo, Bing-he Xu, P. Yuan, 2020, Breast.

An open-label, multicenter, phase Ib study to evaluate RC48-ADC in patients with HER2-positive metastatic breast cancer.

Bing-he Xu, Qingyuan Zhang, Jiayu Wang, 2018 .

Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients

Bing-he Xu, Yunpeng Liu, Xianli Yin, 2022, Chinese medical journal.

Promising efficacy of SHR‐1210, a novel anti–programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China

Bing-he Xu, Weilong Zhang, Y. Jiao, 2018, Cancer.

Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial

Ying Cheng, P. Lu, Bing-he Xu, 2019, Cancer communications.

Time to raise the bar: Transition rate of phase 1 programs on anticancer drugs.

Bing-he Xu, D. Wang, Y. Ba, 2022, Cancer cell.

Anticancer drug R&D landscape in China

Bing-he Xu, Y. Ba, L. Shen, 2020, Journal of Hematology & Oncology.

Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study

Bing-he Xu, Jiachen Xu, B. Lan, 2018, British Journal of Cancer.

Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer

Yang Luo, Bing-he Xu, P. Yuan, 2015, Medicine.

Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study

Bing-he Xu, Q. Sun, Shiying Yu, 2016, Oncotarget.

Neuroendocrine carcinoma of the breast: a review of 126 cases in China

Wenjie Zhu, F. Du, Bing-he Xu, 2017, Chinese journal of cancer.

PRR15 deficiency facilitates malignant progression by mediating PI3K/Akt signaling and predicts clinical prognosis in triple-negative rather than non-triple-negative breast cancer

Bing-he Xu, Jialu Ma, Changyuan Guo, 2023, Cell death & disease.

Survival Outcome and Impact of Chemotherapy in T1 Node-Negative Triple-Negative Breast Cancer: A SEER Database Analysis

Wen-na Wang, Yang Luo, Bing-he Xu, 2020, Journal of oncology.

A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer

Bing-he Xu, P. Yuan, F. Ma, 2021, Frontiers in Oncology.

A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatments

H. Yao, Tao Wang, Bing-he Xu, 2023, International journal of cancer.

Current clinical trials on breast cancer in China: A systematic literature review

Bing-he Xu, Ying Fan, 2020, Cancer.

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).

R. Gelber, J. Baselga, Z. Aziz, 2021, European journal of cancer.

Tumor Microenvironment Subtypes and Immune-Related Signatures for the Prognosis of Breast Cancer

Bing-he Xu, Yiqun Han, Jiayu Wang, 2020, BioMed research international.

RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies.

Yang Luo, Bing-he Xu, Jifeng Feng, 2021 .

Abstract GS1-06: A randomized control phase III trial of entinostat, a once weekly, class I selective histone deacetylase inhibitor, in combination with exemestane in patients with hormone receptor positive advanced breast cancer

Ming Yan, Bing-he Xu, Huiping Li, 2022, Cancer Research.

Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study).

Bing-he Xu, Huiping Li, Q. Sun, 2023, European journal of cancer.

Clinical development of immuno-oncology in China.

Yang Zhao, Ning Li, Jie He, 2020, The Lancet. Oncology.

Targeted therapeutic options and future perspectives for HER2-positive breast cancer.

Bing-he Xu, Jiani Wang, 2019, Signal transduction and targeted therapy.

Risk Factors and Survival of Patients With Liver Metastases at Initial Metastatic Breast Cancer Diagnosis in Han Population

Yang Luo, Bing-he Xu, P. Yuan, 2021, Frontiers in Oncology.

Development and validation of a nomogram for predicting survival of advanced breast cancer patients in China.

Yang Luo, Bing-he Xu, P. Yuan, 2020 .

Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China

Bing-he Xu, Y. Guan, F. Ma, 2020, Cancer communications.

Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4.

Ying Cheng, Chiun-Sheng Huang, Bing-he Xu, 2022, European journal of cancer.

Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

P. Neven, P. Goss, Bing-he Xu, 2014, The oncologist.

Abstract GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03

Sung-Bae Kim, H. Iwata, Yeon-Hee Park, 2022, Cancer Research.

PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03

Sung-Bae Kim, Chiun-Sheng Huang, H. Iwata, 2022, Annals of Oncology.

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer

X. Yi, Wen-na Wang, Bing-he Xu, 2020, NPJ breast cancer.

Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer

Yang Luo, Bing-he Xu, P. Yuan, 2019, Cancer communications.

Olaparib efficacy in patients with germline BRCA‐mutated, HER2‐negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial

M. Robson, Bing-he Xu, N. Tung, 2023, International journal of cancer.

Serum sodium ions and chloride ions associated with taxane-induced peripheral neuropathy in Chinese patients with early-stage breast cancer: A nation-wide multicenter study

Bing-he Xu, Fang Zhao, F. Ma, 2022, Breast.

Docetaxel Plus S-1 versus Docetaxel Plus Capecitabine as First-Line Treatment for Advanced Breast Cancer Patients: A Prospective Randomized Phase II Study

Yang Luo, Bing-he Xu, P. Yuan, 2023, Journal of the National Cancer Center.

The clinical course and treatment results of lung metastases from breast cancer

Bing-he Xu, Yan Sun, Aiping Zhou, 1998, Zhonghua zhong liu za zhi [Chinese journal of oncology].

Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2– advanced breast cancer in Chinese women

Bing-he Xu, Huiping Li, Wei Li, 2021, Cancer Chemotherapy and Pharmacology.

Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study.

Ying Cheng, Bing-he Xu, Z. Guan, 2012, Chinese Medical Journal.

First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers

W. Qiu, B. Ye, Bing-he Xu, 2019, BMC cancer.

Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.

Bing-he Xu, P. Yuan, F. Ma, 2012, Breast.

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients

Bing-he Xu, H. Qian, F. Ma, 2021, Cancer medicine.

Availability of anticancer biosimilars in 40 countries.

Ning Li, Jie He, Bing-he Xu, 2020, The Lancet. Oncology.

Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies

Yang Luo, Bing-he Xu, F. Ma, 2023, Biomarker Research.

A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer

Bing-he Xu, Yiqun Han, Q. Ouyang, 2021, iScience.

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer

X. Yi, Wen-na Wang, Bing-he Xu, 2020, npj Breast Cancer.

Neoadjuvant combination chemotherapy with pegylated liposomal doxorubicin and vinorelbine for locally advanced breast cancer

Bing-he Xu, Z. Shao, Yong-Sheng Wang, 2010 .

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer

S. Loi, G. Hortobagyi, A. Bardia, 2023, Therapeutic advances in medical oncology.

A CLDN1-Negative Phenotype Predicts Poor Prognosis in Triple-Negative Breast Cancer

Bing-he Xu, N. Lu, J. Ying, 2014, PloS one.

Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China

Wen-na Wang, Yang Luo, Bing-he Xu, 2018, International journal of cancer.

Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective

Bing-he Xu, P. Yuan, 2021, Breast cancer.

Paclitaxel plus carboplatin for women with advanced breast cancer.

Bing-he Xu, Long-Mei Zhao, Jiayu Wang, 2007, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih.

[Breast cancer brain metastases: clinical and prognostic characteristics of different biological subtypes].

Bing-he Xu, P. Yuan, F. Ma, 2014, Zhonghua zhong liu za zhi [Chinese journal of oncology].

Primary Tumor Surgery for Patients with De Novo Stage IV Breast Cancer can Decrease Local Symptoms and Improve Quality of Life

Yang Luo, Bing-he Xu, P. Yuan, 2020, Annals of Surgical Oncology.

Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population

Yang Luo, Bing-he Xu, P. Yuan, 2016, Medicine.

Bing-he Xu, M. Desilvio, Zefei Jiang, 2014, Breast Cancer Research.

Abstract OT1-01-01: IMpassion131: A phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (TNBC)

A. Schneeweiss, Bing-he Xu, F. André, 2018 .

Extracellular matrix-derived mechanical force governs breast cancer cell stemness and quiescence transition through integrin-DDR signaling

Bing-he Xu, Liming Ge, L. Yang, 2023, Signal transduction and targeted therapy.

Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first‐line treatment of patients with advanced breast cancer: Phase 3 randomized trial

Yang Luo, Bing-he Xu, P. Yuan, 2015, Cancer.

Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer.

Dianke Yu, Bing-he Xu, T. Sun, 2011, Chinese medical journal.

Cytotoxic Lymphocyte-Related Gene Signature in Triple-Negative Breast Cancer

Bing-he Xu, Yiqun Han, Jiayu Wang, 2023, Journal of personalized medicine.

A Prospective, Randomized, Placebo-Controlled Study Assessing the Efficacy of Chinese Herbal Medicine (Huangqi Guizhi Wuwu Decoction) in the Treatment of Albumin-Bound Paclitaxel-Induced Peripheral Neuropathy

Wen-na Wang, Bing-he Xu, Y. Chai, 2023, Journal of clinical medicine.

Accelerating the integration of China into the global development of innovative anticancer drugs.

Bing-he Xu, Shuhang Wang, H. Miao, 2022, The Lancet. Oncology.

Cardia and Non-Cardia Gastric Cancer Have Similar Stage-for-Stage Prognoses After R0 Resection: a Large-Scale, Multicenter Study in China

F. Du, Bing-he Xu, Faxiang Ji, 2016, Journal of Gastrointestinal Surgery.

Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors

Yang Luo, Bing-he Xu, Naihan Chen, 2023, Investigational New Drugs.

Mechanism of cross‐resistance to cisplatin in a mitomycin C‐resistant human bladder cancer cell line

Bing-he Xu, Shivendra V. Singh, S. Specht, 1995, International journal of cancer.

Mutational characteristics determined using circulating tumor DNA analysis in triple‐negative breast cancer patients with distant metastasis

Bing-he Xu, Y. Guan, Yaping Xu, 2020, Cancer communications.

Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study

Yongmei Yin, Bing-he Xu, Huiping Li, 2022, Breast Cancer Research and Treatment.

Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial.

R. Gelber, J. Baselga, Bing-he Xu, 2017 .

The emerging role of RNA N6-methyladenosine methylation in breast cancer

P. Jin, F. Du, Bing-he Xu, 2021, Biomarker research.

Guidelines on the diagnosis and treatment of breast cancer (2011 edition).

Jie Chen, Li Fu, Bing-he Xu, 2012, Gland surgery.

Phase I clinical and pharmacokinetic study of UTD1, a genetically engineered epothilone analog in patients with advanced solid tumors

Bing-he Xu, Li Tang, G. Dou, 2011, Cancer Chemotherapy and Pharmacology.

Palbociclib plus letrozole as first-line treatment for ER-positive and HER2-negative advanced breast cancer in Chinese women: a phase 1 study

Bing-he Xu, B. Shao, Huiping Li, 2017 .

Profile and outcome of receptor conversion in breast cancer metastases: a nation‐wide multicenter epidemiological study

Y. Qiao, Jin-Hu Fan, Wen-na Wang, 2020, International journal of cancer.

GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer.

Sung-Bae Kim, Chiun-Sheng Huang, H. Rugo, 2022, Future oncology.

TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.

A. Bardia, H. Rugo, Bing-he Xu, 2023, Future Oncology.

Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis

H. Iwata, M. Robson, Yeon-Hee Park, 2020, Scientific Reports.

[Clinical features and prognosis in breast cancer patients over 70 years of age].

Bing-he Xu, Yan Sun, Pin Zhang, 2006, Zhonghua zhong liu za zhi [Chinese journal of oncology].

Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience

Bing-he Xu, M. Ramos-Suzarte, Shuping Xu, 2016, Oncotarget.

LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment.

Chiun-Sheng Huang, Bing-he Xu, N. Harbeck, 2012 .

The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 status

Bing-he Xu, Qiao Li, Mingxia Jiang, 2023, International journal of cancer.

A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer

H. Yao, Ming Yan, Ying Cheng, 2022, Therapeutic advances in medical oncology.

Consistent efficacy and safety of gemcitabine–paclitaxel in patients with metastatic breast cancer: A retrospective comparison of East Asian and global studies

Bing-he Xu, M. Orlando, Zhixin Liu, 2014, Asia-Pacific journal of clinical oncology.

Ganglioside Monosialic Acid Alleviates Peripheral Neuropathy Induced by Utidelone Plus Capecitabine in Metastatic Breast Cancer From a Phase III Clinical Trial

Bing-he Xu, Yan Wang, T. Sun, 2020, Frontiers in Oncology.

Stem Cell Marker Aldehyde Dehydrogenase 1 (ALDH1)-Expressing Cells are Enriched in Triple-Negative Breast Cancer

Bing-he Xu, Hai-juan Wang, Chen Lin, 2013, The International journal of biological markers.

Young breast cancer patients who develop distant metastasis after surgery have better survival outcomes compared with elderly counterparts

Yang Luo, Bing-he Xu, P. Yuan, 2017, Oncotarget.

Prognostic Model and Nomogram for Estimating Survival of Small Breast Cancer: A SEER-based Analysis.

Yanxia Sun, Yang Luo, Bing-he Xu, 2020, Clinical breast cancer.

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Wei Li, B. Xu, M. Robson, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis

Bing-he Xu, Y. Wang, Yan Wang, 2023, ESMO open.

A phase III, randomized, double-blind, placebo (Pla)-controlled study of pertuzumab (P) + trastuzumab (H) + docetaxel (D) versus Pla + H+ D in previously untreated HER2-positive locally recurrent/metastatic breast cancer (LR/MBC) (PUFFIN).

Yongmei Yin, Bing-he Xu, Huiping Li, 2019, Journal of Clinical Oncology.

Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study.

Chiun-Sheng Huang, Bing-he Xu, Z. Shao, 2021, Japanese Journal of Clinical Oncology.

Real‐world treatment patterns and outcomes of pyrotinib‐based therapy in patients with HER2‐positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study

Wei Li, Bing-he Xu, Jin Yang, 2023, International journal of cancer.

Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first‐line options for HER2‐positive relapsed or metastatic breast cancer

Bing-he Xu, X. Guan, F. Ma, 2022, Cancer Innovation.

Abstract GS3-02: Updated overall survival (OS) results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine in patients with HER2-positive metastatic breast cancer

Ming Yan, Ying Cheng, Yongmei Yin, 2022, Cancer Research.

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

M. Piccart, C. Hudis, L. Norton, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer

Yang Luo, Bing-he Xu, F. Ma, 2023, Signal Transduction and Targeted Therapy.

CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis

Yang Luo, Bing-he Xu, Jiayu Wang, 2023, BMC Cancer.

Abstract GS2-02: GS2-02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03

H. Iwata, Bing-he Xu, G. Curigliano, 2023, Cancer Research.

Abstract P1-13-11: Neratinib in the extended adjuvant treatment of patients from Asia with early-stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial

H. Iwata, Bing-he Xu, J. Chiu, 2018 .

TNM stage at diagnosis is more predictive of prognosis than pathological complete response in young breast cancer treated with neoadjuvant chemotherapy

Yang Luo, Bing-he Xu, P. Yuan, 2017, Anti-cancer drugs.

Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients

Bing-he Xu, Z. Shao, W. Yeo, 2011, Chinese journal of cancer.

The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population

Yang Luo, Bing-he Xu, P. Yuan, 2018, International journal of cancer.

Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial.

S. Loi, G. Hortobagyi, A. Bardia, 2023, Journal of Clinical Oncology.

A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer

Yang Luo, Bing-he Xu, Y. Chai, 2023, Thoracic cancer.

[Clinical characteristics and potential prognostic factors of breast cancer patients with liver metastases].

Bing-he Xu, Jiayu Wang, Yan Wang, 2006, Zhonghua zhong liu za zhi [Chinese journal of oncology].

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

A. Tutt, M. Piccart, C. Hudis, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Icaritin efficacy and tolerability in advanced hepatocellular carcinoma: Final phase Ib result.

Bing-he Xu, P. Yuan, Kun Meng, 2014 .

A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290).

H. Iwata, M. Robson, Yeon-Hee Park, 2020 .

Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial

Ming Yan, Lisong Yang, Bing-he Xu, 2023, Acta pharmaceutica Sinica. B.

Abstract 1660: Preliminary safety tolerability & efficacy results of KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with Nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC)

Bing-he Xu, Qiang Liu, Jing Yang, 2021, Immunology.

Neratinib-based therapy in patients with metastatic HER2-positive breast cancer from Asia.

Sung-Bae Kim, L. Chow, Bing-he Xu, 2019, Future oncology.

5050 POSTER Lapatinib (L) in Combination With Paclitaxel (P) is an Effective and Tolerable Treatment in HER2-overexpressing Metastatic Breast Cancer (MBC) Patients

Bing-he Xu, M. Desilvio, B. Newstat, 2011 .

Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.

Bing-he Xu, L. Dirix, A. Awada, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Utilizing Tumor and Plasma Liquid Biopsy in Treatment Decision Making for an Estrogen Receptor-Positive Advanced Breast Cancer Patient

B. Leyland-Jones, Bing-he Xu, P. De, 2017, Cureus.

EGFR基因rs2293347多态对吉非替尼治疗非小细胞肺癌临床疗效的影响

D. Lin, Bing-he Xu, T. Sun, 2011, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Sung-Bae Kim, E. Perez, R. Gelber, 2014, The Lancet. Oncology.

Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.

H. Gómez, Bing-he Xu, M. Desilvio, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel Plus Bevacizumab Versus Paclitaxel Alone for Metastatic Breast Cancer

Bing-he Xu, X. Bing-he, 2008 .

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

Eld, M. Piccart, C. Hudis, 2014, Breast.

Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib.

Chen Wu, D. Lin, Dianke Yu, 2009, Lung cancer.

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Sung-Bae Kim, S. Loi, Chiun-Sheng Huang, 2022, The Lancet.

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

C. Isaacs, Bing-he Xu, F. André, 2014, The Lancet. Oncology.

Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.

Bing-he Xu, L. Dirix, A. Awada, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase 3, randomized, open-label study of the anti-Globo H vaccine adagloxad simolenin/obi-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer.

Sung-Bae Kim, Chiun-Sheng Huang, H. Rugo, 2022, Journal of Clinical Oncology.

[Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].

X. Miao, Bing-he Xu, P. Yuan, 2005, Zhonghua yi xue za zhi.

E. Song, Bing-he Xu, Wentao Yang, 2015, Oncotarget.

Prognostic Factors and a Model for Occult Breast Cancer: A Population-Based Cohort Study

Bing-he Xu, F. Ma, Lixi Li, 2022, Journal of clinical medicine.

Combined chemo-endocrine therapy as a potential new option for HR+/HER2− advanced breast cancer: a prospective study of fulvestrant plus oral vinorelbine

Bing-he Xu, P. Yuan, J. Ju, 2023, Cancer biology & medicine.

Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer.

A. Buzdar, B. Xu, Bing-he Xu, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Y. Wang, Ying Cheng, Bing-he Xu, 2023, The Lancet. Oncology.

[Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy].

X. Miao, Bing-he Xu, P. Yuan, 2005, Ai zheng = Aizheng = Chinese journal of cancer.